ARCH leads $34 mln Series A financing in Sienna Biopharmaceuticals

ARCH Venture Partners led a $34 million Series A financing in Sienna Biopharmaceuticals, Inc., which is pursuing new technologies in medical aesthetics and dermatology. Altitude Life Science Venture Partners, Partner Fund Management, and Venvest Capital also invested in the development stage company.

North AmericaUSBriefs